Dr. Selina Laqui, MD, PhD
Claim this profileUniversity of California Davis Comprehensive Cancer Center
Studies Oligoprogressive
Studies Lymphoma
10 reported clinical trials
20 drugs studied
Area of expertise
1Oligoprogressive
Stage IV
2Lymphoma
Stage II
Stage III
Stage IV
Affiliated Hospitals
Clinical Trials Selina Laqui, MD, PhD is currently running
Loncastuximab Tesirine + Rituximab
for Diffuse Large B-Cell Lymphoma
This phase II trial evaluates whether loncastuximab tesirine and rituximab followed by dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone works to treat patients with high risk diffuse large B-cell lymphoma. Loncastuximab tesirine is a monoclonal antibody called loncastuximab, linked to a drug called tesirine. It is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as CD19 receptors, and delivers tesirine to kill them. Rituximab is a monoclonal antibody. It binds to a protein called CD20, which is found on B cells (a type of white blood cell) and some types of cancer cells. This may help the immune system kill cancer cells. Chemotherapy drugs such as doxorubicin, vincristine, and cyclophosphamide work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair and may kill cancer cells. Prednisone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response to help lessen the side effects of chemotherapy drugs. Giving loncastuximab tesirine and rituximab in combination with dose-adjusted doxorubicin, etoposide, vincristine, cyclophosphamide, and prednisone may be more effective at treating high risk diffuse large B-cell lymphoma patients than standard treatments.
Recruiting1 award Phase 2
Triple Drug Therapy
for Follicular Lymphoma
This phase II trial studies how well obinutuzumab, ibrutinib, and venetoclax work in treating patients with previously untreated stage II-IV follicular lymphoma. Immunotherapy with obinutuzumab may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Ibrutinib and venetoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving obinutuzumab, ibrutinib, and venetoclax together may work better in treating follicular lymphoma compared to each drug alone.
Recruiting1 award Phase 210 criteria
More about Selina Laqui, MD, PhD
Clinical Trial Related3 years of experience running clinical trials · Led 10 trials as a Principal Investigator · 8 Active Clinical TrialsTreatments Selina Laqui, MD, PhD has experience with
- Cyclophosphamide
- Locally Ablative Therapy
- Venetoclax
- Locally Ablative Therapy
- Etoposide
- Rituximab
Breakdown of trials Selina Laqui, MD, PhD has run
Oligoprogressive
Lymphoma
Prostate Cancer
Parotid Gland Cancer
Mediastinal Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Selina Laqui, MD, PhD specialize in?
Is Selina Laqui, MD, PhD currently recruiting for clinical trials?
Are there any treatments that Selina Laqui, MD, PhD has studied deeply?
What is the best way to schedule an appointment with Selina Laqui, MD, PhD?
What is the office address of Selina Laqui, MD, PhD?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.